PDGFRB

(redirected from PDGFR-beta)

PDGFRB

A gene on chromosome 5q33.1 that encodes a tyrosine-protein kinase which acts as a cell surface receptor for homodimeric PDGFB and PDGFD and for PDGFA and PDGFB heterodimers, playing a key role in regulating embryonic development; cell proliferation, survival, differentiation, chemotaxis and migration; blood vessel development by promoting proliferation, migration and recruitment of pericytes and smooth muscle cells to endothelial cells; and migration of vascular smooth muscle cells and formation of neointima at sites of vascular injury sites. It is required for normal development of the cardiovascular system, for recruitment of mesangial cells and for development of the capillary network in the glomeruli.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
The team was able to achieve this by using a small interfering ribonucleic acid (siRNA) to target a specific gene called PDGFR-beta in the female reproductive tract, which creates a protein that binds to Chlamydia bacteria.
Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse.
Lenvatinib, discovered and developed by Eisai, is an orally active, selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, including KDR (VEGFR-2), Flt-1 (VEGFR-1), RET, FGFR1, PDGFR-Beta and c-kit, involved in angiogenesis and tumor proliferation.
The inhibitory concentration ([IC.sub.50]) of sunitinib is 143 for PDGFR-alpha, 75 for PDGFR-beta, 21 and 34 for VEGFR 1 and VEGFR 2, respectively [5], which is higher than [IC.sub.50] for other tyrosine kinase inhibitors, making sunitinib one of the most potent inhibitors of VEGFR and PDGFR.
The team found that FOXC2 also regulates the platelet derived growth factor receptor (PDGFR-Beta).
Mani said the team believes that targeting FOXC2 pathway using either PDGFR-beta inhibitors or other yet-to-be-known small-molecule inhibitors will be an effective therapeutic strategy for inhibiting EMT and consequently reducing EMT/cancer stem cell-associated metastasis, relapse and therapy resistance.
One typical marker of mural cells is platelet derived growth factor receptor Beta (PDGFR-Beta).
A preliminary study on the changes of expression of PDGF-beta, PDGFR-beta, TGF-beta 1, TGFR, bFGF and its relationship with the wound age in wound healing.
In pre-clinical testing, XL999 inhibited KDR, FGFR1, PDGFR-beta and FLT3 with high potency.
The partnership will develop an innovative antibody to the Platelet Derived Growth Factor Receptor Beta (PDGFR-beta) as a potential combination therapy with EYLEA (aflibercept) for the treatment of wet age-related macular degeneration (wet AMD).